Blueprint Medicines (BPMC) Tops Q1 EPS by 11c
Tweet
Share
E-mailGet Alerts BPMC Hot Sheet
Join SI Premium – FREE
Blueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($1.79), $0.11 better than the analyst estimate of ($1.90). Revenue for the quarter came in at $62.73 million versus the consensus estimate of $38.96 million.
For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nebius soars on second quarter revenue beat
- Kamada Ltd. (KMDA) Tops Q2 EPS by 4c
- Nebius Group (NBIS) Q2 Revenue Tops Consensus
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
